San Diego, CA, United States
San Diego, CA, United States

Time filter

Source Type

Patent
Optimer Pharmaceuticals | Date: 2014-05-19

Methods, processes and materials for the production and recovery of Tiacumicins produced by culturing a microorganism belonging to the species Dactylosporangium aurantiacum subspecies hamdenensis having the ability to produce and accumulate one or more Tiacumicin in a nutrient medium comprising a carbon source, a nitrogen source, trace elements such as inorganic salts, and an adsorbent, wherein said nitrogen source comprises fish powder, and wherein said Tiacumicin is produced in a yield greater than about 50 mg/L broth.


The present invention relates to methods of treating Clostridium difficile infection in a subject receiving antibiotic therapy for a different infection comprising administering to the subject an effective amount of the compounds described herein.


Patent
Optimer Pharmaceuticals | Date: 2013-11-20

A compound according to the formula


Patent
Optimer Pharmaceuticals | Date: 2015-04-15

Methods, processes and materials for the production and recovery of Tiacumicins produced by culturing a microorganism belonging to the species Dactylosporangium aurantiacum subspecies hamdenensis having the ability to produce and accumulate one or more Tiacumicin in a nutrient medium comprising a carbon source, a nitrogen source, trace elements such as inorganic salts, and an adsorbent, wherein said nitrogen source comprises fish powder, and wherein said Tiacumicin is produced in a yield greater than about 50 mg/L broth.


Patent
Optimer Pharmaceuticals | Date: 2014-09-03

This invention relates to novel macrolides, to the preparation of novel macrolides, to the use of such novel macrolides for preventing, treating, or ameliorating various conditions, and to the use of such novel macrolides as antibacterial agents.


Patent
Optimer Pharmaceuticals | Date: 2013-03-15

The present invention relates to methods of preventing Clostridium difficile infection (COI) in a human subject who is at high risk of developing this infection, comprising administering to the subject an effective amount of the compounds described herein. In some embodiments, the subject is further receiving concomitant antibiotic therapy to prevent and/or treat an infection other than Clostridium. In some embodiments, the subject previously was treated for a Clostridium infection. In some embodiments, the compound of formula I prevents the Clostridium infection.


Patent
Optimer Pharmaceuticals | Date: 2013-03-15

The invention encompasses an active metabolite of the 18-membered macrocyclic antimicrobial agents, specifically, a metabolite of tiacumicin B and in certain embodiments, R-Tiacumicin B or and its related compounds. In particular, the invention encompasses a compound that acts as a potent antibiotic agent for the treatment of bacterial infections, specifically GI infections caused by toxin producing strains of Clostridium difficile (C. difficile) and Clostridium perfringens (C. perfringens).


Patent
Optimer Pharmaceuticals | Date: 2013-03-15

The present invention relates generally to the 18-membered macrocyclic antimicrobial agents called Tiacumicins, specifically, OPT-80 (which is composed almost entirely of the R-Tiacumicin B), pharmaceutical compositions comprising OPT-80, and methods using OPT-80. In particular, this compound is a potent drug for the treatment of bacterial infections, specifically C. difficile infections.


The invention relates to novel forms of compounds displaying broad spectrum antibiotic activity, especially crystalline polymorphic forms and amorphous forms of such compounds, compositions comprising such crystalline polymorphic forms and amorphous forms of such compounds, processes for manufacture and use thereof. The compounds and compositions of the invention are useful in the pharmaceutical industry, for example, in the treatment or prevention of diseases or disorders associated with the use of antibiotics, chemotherapies, or antiviral therapies, including, but not limited to, colitis, for example, pseudo-membranous colitis; antibiotic associated diarrhea; and infections due to Clostridium difficile (C. difficile), Clostridium perfringens (C. perfringens), Staphylococcus species, for example, methicillin-resistant Staphylococcus, or Enterococcus including Vancomycin-resistant enterococci.


Patent
Optimer Pharmaceuticals | Date: 2014-11-14

The present invention relates to methods of preventing and/or treating Clostridium difficile infection (CDI) in a subject at high risk for developing CDI including subjects receiving antibiotic therapy for a different infection comprising administering to the subject an effective amount of the compounds described herein.

Loading Optimer Pharmaceuticals collaborators
Loading Optimer Pharmaceuticals collaborators